FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, announced that the first phase of its expansion at the Hillerød site is ready to bring the new production capacity into operation.This milestone marks the initial step in the company’s strategy to build a comprehensive global ecosystem dedicated to enhancing the production and delivery of medicines.
This first phase adds six mammalian cell bioreactors, bringing the total capacity at the Hillerød site to 12 x 20,000 L bioreactors. A previously announced major capital investment will support the next phase, which will include an additional 8 x 20,000 L bioreactors and two downstream processing streams. By mid-2025, fill/finish production is scheduled to commence, with full expansion expected to be in operation by 2026, increasing the site footprint to approximately 51,500 m² and creating up to 2,200 jobs.
Since 2011, FUJIFILM Corporation has invested over $8 billion to establish a global network for biologics manufacturing. This includes strategically located modular facilities designed to provide the agility needed for rapid production scaling. In 2025, operations will begin at the first phase of FUJIFILM Diosynth Biotechnologies’ large-scale facility in Holly Springs, North Carolina.
The company also announced that TG Therapeutics has committed to a multi-year manufacturing supply agreement for BRIUMVI (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS).
Under the terms of the manufacturing supply agreement, FUJIFILM Diosynth Biotechnologies will provide secondary U.S.-based manufacturing supply for BRIUMVI at Holly Springs.
“This commitment recognizes the expertise, capacity and capabilities that FUJIFILM Diosynth Biotechnologies provides with our fully integrated manufacturing network,” said Lars Petersen, president and chief executive officer, FUJIFILM Diosynth Biotechnologies. “FUJIFILM Diosynth Biotechnologies is executing an aggressive expansion strategy, providing customers access to our manufacturing network across the United States, Europe, and Japan for the purpose of meeting the growing demand for biotherapeutics and ultimately making patients’ lives better.”
